PMID- 28345809
OWN - NLM
STAT- MEDLINE
DCOM- 20171116
LR  - 20221207
IS  - 1930-739X (Electronic)
IS  - 1930-7381 (Linking)
VI  - 25
IP  - 5
DP  - 2017 May
TI  - Effect of lorcaserin on glycemic parameters in patients with type 2 diabetes 
      mellitus.
PG  - 842-849
LID - 10.1002/oby.21798 [doi]
AB  - OBJECTIVE: Lorcaserin, a 5-HT(2C) receptor agonist approved for chronic weight 
      management, is also associated with improvements in glycemic parameters in 
      patients with/without type 2 diabetes mellitus (T2DM), but the extent to which 
      these effects are mediated by weight loss is unknown. This post hoc analysis 
      further examines glycemic data from the Phase III BLOOM-DM study stratified by 
      weight changes. METHODS: Patients with T2DM were randomized to lorcaserin 10 mg 
      twice daily or placebo. Glycemic parameters were reported by Week (W) 12 weight 
      loss status >/=5% (Group >/=5%) or <5% (Group <5%). Glycemic parameter changes were 
      analyzed using ANCOVA; the relationship between glycemic parameter changes and 
      percent weight loss was assessed by simple regression modeling. RESULTS: Group 
      >/=5% receiving lorcaserin had greater improvements in fasting plasma glucose (FPG) 
      at W2 (prior to significant weight loss) and greater improvements in glycated 
      hemoglobin (HbA1c) at W12 versus placebo. These improvements were maintained 
      through W52 (FPG, -29.3 mg/dL vs. -24.2 mg/dL; HbA1c, -1.2% vs. -1.1%). Group <5% 
      treated with lorcaserin also had larger decreases in FPG (-28.3 mg/dL vs. -10.0 
      mg/dL) and HbA1c (-0.8% vs. -0.4%) at W52 versus placebo despite limited weight 
      loss. CONCLUSIONS: Lorcaserin may have beneficial effects on glycemic control 
      with or without weight loss.
CI  - (c) 2017 The Obesity Society.
FAU - Magkos, Faidon
AU  - Magkos F
AD  - Department of Physiology, Yong Loo Lin School of Medicine, National University of 
      Singapore & Clinical Nutrition Research Centre, Singapore Institute for Clinical 
      Sciences, Agency for Science, Technology and Research (A*STAR), Singapore.
FAU - Nikonova, Elena
AU  - Nikonova E
AD  - Eisai Medical and Scientific Affairs, Eisai Inc, Woodcliff Lake, New Jersey, USA.
FAU - Fain, Randi
AU  - Fain R
AD  - Mallinckrodt Pharmaceuticals, Hampton, New Jersey, USA.
FAU - Zhou, Sharon
AU  - Zhou S
AD  - Eisai Medical and Scientific Affairs, Eisai Inc, Woodcliff Lake, New Jersey, USA.
FAU - Ma, Tony
AU  - Ma T
AD  - Janssen Research & Development, LLC, Raritan, New Jersey, USA.
FAU - Shanahan, William
AU  - Shanahan W
AD  - Anthera Pharmaceuticals, Hayward, California, USA.
LA  - eng
SI  - ClinicalTrials.gov/NCT00603291
PT  - Journal Article
PT  - Multicenter Study
PT  - Randomized Controlled Trial
DEP - 20170327
PL  - United States
TA  - Obesity (Silver Spring)
JT  - Obesity (Silver Spring, Md.)
JID - 101264860
RN  - 0 (Benzazepines)
RN  - 0 (Blood Glucose)
RN  - 0 (Glycated Hemoglobin A)
RN  - 637E494O0Z (lorcaserin)
SB  - IM
CIN - Obesity (Silver Spring). 2017 May;25(5):816. PMID: 28371396
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Benzazepines/administration & dosage/pharmacology/*therapeutic use
MH  - Blood Glucose/*drug effects
MH  - Diabetes Mellitus, Type 2/blood/*drug therapy
MH  - Double-Blind Method
MH  - Female
MH  - Glycated Hemoglobin/analysis/*drug effects
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Retrospective Studies
MH  - Young Adult
EDAT- 2017/03/28 06:00
MHDA- 2017/11/29 06:00
CRDT- 2017/03/28 06:00
PHST- 2016/08/02 00:00 [received]
PHST- 2016/12/22 00:00 [revised]
PHST- 2017/01/13 00:00 [accepted]
PHST- 2017/03/28 06:00 [pubmed]
PHST- 2017/11/29 06:00 [medline]
PHST- 2017/03/28 06:00 [entrez]
AID - 10.1002/oby.21798 [doi]
PST - ppublish
SO  - Obesity (Silver Spring). 2017 May;25(5):842-849. doi: 10.1002/oby.21798. Epub 
      2017 Mar 27.